Valued at US$ 725 million in 2023, the global market for cirrhosis management is likely to exhibit a CAGR of 3.8% during the forecast period, reaching US$ 1,052.3 million by 2033. The market exhibited a compounded growth rate of 2.7% from 2018 to 2022. Expansion of the market can be attributed to the increasing incidences of liver cirrhosis due to rise in the hepatitis infections across the globe.
| Data Points | Key Statistics |
|---|---|
| Expected Base Year Value (2022) | US$ 701.8 million |
| Projected Market Value (2023) | US$ 725 million |
| Anticipated Forecast Value (2033) | US$ 1,052.3 million |
| Estimated Growth Rate (2023 to 2033) | 3.8% |
Cirrhosis is a late-stage result of liver disease and its complications. Common causes of Cirrhosis include alcohol abuse, hepatitis, and nonalcoholic fatty liver disease. Treatment and Management of Cirrhosis depends on the cause of the disease and how much damage exists. Liver transplantation may be an option if one’s liver is failing, due to disease.
As per the National Center for Biotechnology Information (NCBI), liver disease claims about 2 million deaths globally, every year. Currently, Cirrhosis is the 11th most cause of death. Due to aggravating situation, players in the market are taking various initiatives to tackle the worsening condition, which is expected to benefit the industry in the coming time.
In September 2019, Versantis raised a Series B of € 14.6 Million to develop its treatment for late-stage liver cirrhosis in a phase II trial. Post the II trial, the company announced that it is projected to use the funds to launch a phase IIa trial of the treatment in early 2020. Such factors are expected to benefit the cirrhosis management market in the forecast period.
Increasing incidences of liver cirrhosis due to rise in the hepatitis infections across the globe is one of the major factors that is expected to accelerate the growth of the global Cirrhosis Management Market over the analysis period.
On the contrary, the high cost associated with drug development is one of the major factors that is expected to hinder the growth of the cirrhosis management market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The increase in the occurrence of liver cirrhosis due to the rise in hepatitis infections is one of the major factors that is anticipated to boost the growth of the global liver cirrhosis management market during the forecast period.
The rise in the number of people suffering from liver cirrhosis can be attributed to rapidly changing lifestyles such as an increase in alcohol consumption and an unbalanced diet. Hence, the rise in the prevalence of the disease is projected to fuel the growth of the global market during the forecast period.
According to the National Center for Biotechnology Information (NCBI), around 2 billion people consume alcohol worldwide, and upwards of 75 million are diagnosed with alcohol-use disorders and are at risk of alcohol-associated liver disease. Nearly 2 billion adults are obese or overweight and over 400 million have diabetes; both of which are risk factors for non-alcoholic fatty liver disease and hepatocellular carcinoma.
An increase in awareness programs and a rise in research & development investment for the development of new drug molecules are expected to augment the global liver cirrhosis management market in the forthcoming years. In addition, the rise in government-driven initiatives in the field of liver cirrhosis treatment is another factor that is expected to propel the global market shortly.
According to WHO, alcohol consumption is expected to cause 20% to 50% of liver cirrhosis cases. Also, the increasingly obese populace is expected to grow the risk of non-alcoholic fatty liver disease caused due to build-up of fat in the liver. Other vital factors contributing to the market growth include increased R&D, growing public awareness, and expanding geriatric population.
The increasing initiative of players to launch innovative tools is projected to be an effective factor in developing the market. For instance, in March 2022, Echosens, a high-tech company offering the FibroScan ® portfolio of solutions, announced the launch of FibroScan GO, a cost-effective tool for screening lover health and improving liver health management at the point of care for primary care practices. Attributed to such factors, the market is anticipated to grow significantly in the forecast period.
Stringent regulatory approvals and delayed approvals for novel drugs and vaccines are one of the major factors that are anticipated to impede the growth of the cirrhosis management market during the forecast period. Also, side effects associated with products (fever, depression, and fatigue) is another vital factor that is expected to hamper the market growth in the coming time.
Moreover, the high cost associated with drug development is also a major factor that is expected to limit the growth of the cirrhosis management market over the analysis period. However, ongoing research studies and clinical trials for the treatment of liver disease are expected to act as a significant counter to the hampering causes and propel market growth in the coming time.
For instance, in March 2022, Siemens Healthineers launched Enhanced Liver Fibrosis (ELF) Test in the United States. It provides clinical access to the minimally invasive prognostic tool. Thus, the market is likely to expand significantly in the coming time.
Principal Consultant
| Region | North America |
|---|---|
| Market Share % (2022) | 39.2% |
In terms of regional platforms, North America holds the largest market share in the Cirrhosis Management market. The region gained a market share of 39.2% share in 2022. Developed nations like the United States, Canada, and others are expected to make the maximum contribution to strengthen the growth of the cirrhosis management industry. Domination of the region can be attributed to the presence of major players like Astellas Pharma Inc., Mylan, AbbVie Inc., Merck & Co., Inc., and others.
Ongoing development in the field is anticipated to offer significant results to the market. For instance, in December 2019, Gilead Sciences, Inc. announced topline results from the 48-week, Phase 2 ATLAS study of combination and monotherapy investigational treatments for advanced fibrosis due to Nonalcoholic Steatohepatitis (NASH).
The study resulted in the improvement of various measures of fibrosis and liver injury with the investigational first cost at and cilofexor. Attributed to such factors, the market in North America is expected to develop significantly in the forecast period.
Moreover, a favorable reimbursement scenario, an increase in research and development investments in pharmaceutical companies & research institutes for new drug development, and the presence of major players in the region are some major factors that are expected to fuel the market growth during the forecast period.
| Region | Europe |
|---|---|
| Market Share % (2022) | 26.7% |
According to Future Market Insights, Europe is expected to hold significant growth opportunities for cirrhosis management and reached a share of 26.7% in 2022.
According to the WHO, about 1.8% of all deaths in Europe are caused due to liver cirrhosis. Continuous efforts taken by the players in the market are likely to provide a significant boost to market growth in the coming time. For instance, in March 2021, A-Tango Consortium, a five-year project that receives funding from European Union’s Horizon 2020, was launched.
A-Tango Consortium will perform Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves liver regeneration, the novel therapy is called G-TAK. Owing to such innovations in the region, the European market is anticipated to augment significantly in the forecast period.
Europe is likely to be the second largest market for liver cirrhosis treatment during the forecast period, owing to a rise in awareness about new treatment options and a developed regulatory framework in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Countries | Market Forecast % (2023 to 2033) |
|---|---|
| China | 4.3% |
| India | 4.1% |
According to Future Market Insights, Asia-Pacific is expected to grow with lucrative growth opportunities for the cirrhosis management industry.
Asia-Pacific is anticipated to witness notable growth, owing to a rise in research and development activities, a surge in liver diseases, unmet medical demands, and an increase in investments in the healthcare sector in the region.
Moreover, an increase in the consumption of alcohol, an unhealthy lifestyle leading to obesity & weight gain, the presence of key players, and a rise in healthcare expenditure in the region are some of the major factors that are anticipated to augment the growth of the cirrhosis management market over the analysis period.
In addition, the rise in the prevalence of liver diseases and improving healthcare infrastructure are other factors propelling the market growth in the region.
According to Future Market Insights, the Middle East & Africa are expected to provide significant growth opportunities for the cirrhosis management industry.
The Middle East & Africa is expected to have significant growth in the cirrhosis management industry during the forecast period. The rising patient population suffering from liver cirrhosis is one of the major factors that is anticipated to escalate the market growth in the region.
The region is projected to have lucrative growth opportunities, attributed to the rapidly developing healthcare amenities among Saudi Arabia, Oman, and Qatar. Over 200,000 deaths took place in Sub-Saharan Africa due to liver diseases resulting in liver cirrhosis. More than 80% of Africa’s liver disease burden is due to endemic blood-borne virus infections like HIV, hepatitis B, and hepatitis C.
Additionally, the market Middle East & Africa is anticipated to expand at a steady pace, attributed to the presence of rapidly developing economies and evolving healthcare infrastructure in these regions.
There are many prominent market players in the Cirrhosis Management Market such as Galea Therapeutics, Akero Therapeutics, Inorbit Therapeutics, Ochre Bio, Ezra, Jetra Therapeutics, Moderna Therapeutics, Translate Bio, Promethera Biosciences, and AgomAb Therapeutics, among others, which are working hand-in-hand to provide the best-in-class Cirrhosis Management for enhancing the global arena.
However, there are many global start-ups in the Cirrhosis Management Market, that are stepping forward in matching the requirements of the Cirrhosis Management domain.
Founded in 2017, Akero Therapeutics is a clinical-stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical needs. The company aims to advance its lead program efruxifermin (EFX), to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Some of the key participants present in the global Cirrhosis Management market include Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, B. Braun Medical Inc., Conatus Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Stempeutics Research Pvt Ltd, Epic Research & Diagnostics, Inc., Inc., and NovaShunt AG among others.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Theravance Biopharma R&D, Alliancells Bioscience Corporation Limited, and B. Braun Medical Inc., account for a considerable market size, several regional-level players are also operating across key growth regions, particularly in North America.
Recent Key Developments in the Market Include
| Report Attributes | Details |
|---|---|
| Growth Rate | 3.8% CAGR from 2023 to 2033 |
| Market Value in 2023 | US$ 725 million |
| Market Value in 2033 | US$ 1,052.3 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ million for Value |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available upon Request |
The leading Asian nations in the market for cirrhosis management are China, India, Japan, and South Korea.
The primary consumer of the cirrhosis management market is the healthcare sector.
The cirrhosis management market growth is predicted to be 4.3% in China and 4.1% in India by 2033
The cirrhosis management market is currently valued at US$ 1052.3 million.
Cirrhosis management is anticipated to be worth USD 1,052.3 million by 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Treating Cirrhosis Causes 5.3.2. Antiviral Medications for Hepatitis B & C 5.3.3. Corticosteroids 5.3.4. Symptomatic Treatment 5.3.5. Analgesics 5.3.6. Treatment of Portal Hypertension 5.3.7. Treatment of Edema and Ascites 5.3.8. Avoid Complications 5.3.9. Banding Procedures/Band Ligation of Varics 5.3.10. Dialysis 5.3.11. Treatment of Osteoporosis 5.3.12. Vaccination for Flu and Other Complications 5.3.13. Liver Transplantation 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033 6.3.1. Alcoholic Liver 6.3.2. Non-Alcoholic Liver 6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Ambulatory Surgical Centers 7.3.3. Research Institutes 7.3.4. Dialysis Centers 7.3.5. Clinics 7.3.6. Other Settings 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Treatment 9.2.3. By Disease Indication 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By Disease Indication 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Treatment 10.2.3. By Disease Indication 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By Disease Indication 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Treatment 11.2.3. By Disease Indication 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By Disease Indication 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Treatment 12.2.3. By Disease Indication 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By Disease Indication 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Treatment 13.2.3. By Disease Indication 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By Disease Indication 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Treatment 14.2.3. By Disease Indication 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By Disease Indication 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Treatment 15.2.3. By Disease Indication 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Treatment 15.3.3. By Disease Indication 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Treatment 16.1.2.2. By Disease Indication 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Treatment 16.2.2.2. By Disease Indication 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Treatment 16.3.2.2. By Disease Indication 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Treatment 16.4.2.2. By Disease Indication 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Treatment 16.5.2.2. By Disease Indication 16.5.2.3. By End User 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Treatment 16.6.2.2. By Disease Indication 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Treatment 16.7.2.2. By Disease Indication 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Treatment 16.8.2.2. By Disease Indication 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Treatment 16.9.2.2. By Disease Indication 16.9.2.3. By End User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Treatment 16.10.2.2. By Disease Indication 16.10.2.3. By End User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Treatment 16.11.2.2. By Disease Indication 16.11.2.3. By End User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Treatment 16.12.2.2. By Disease Indication 16.12.2.3. By End User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Treatment 16.13.2.2. By Disease Indication 16.13.2.3. By End User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Treatment 16.14.2.2. By Disease Indication 16.14.2.3. By End User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Treatment 16.15.2.2. By Disease Indication 16.15.2.3. By End User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Treatment 16.16.2.2. By Disease Indication 16.16.2.3. By End User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Treatment 16.17.2.2. By Disease Indication 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Treatment 16.18.2.2. By Disease Indication 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Treatment 16.19.2.2. By Disease Indication 16.19.2.3. By End User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Treatment 16.20.2.2. By Disease Indication 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Treatment 16.21.2.2. By Disease Indication 16.21.2.3. By End User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Treatment 16.22.2.2. By Disease Indication 16.22.2.3. By End User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Treatment 16.23.2.2. By Disease Indication 16.23.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Treatment 17.3.3. By Disease Indication 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. B. Braun Medical Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Alliancells Bioscience Corporation Ltd. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Histogen Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Stempeutics Research Pvt. Ltd. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Epic Research & Diagnostics Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Theravance Biopharma R&D Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Sequana Medical AG 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. NovaShunt AG 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Conatus Pharmaceuticals Inc., 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Merck Sharp & Dohme Corp. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Cirrhosis Management Market
